Clinical Challenges and Limitations in β-Thalassaemia Treatment and Their Impact on Patient Outcomes - European Medical Journal

Clinical Challenges and Limitations in β-Thalassaemia Treatment and Their Impact on Patient Outcomes

Hematology

The first of our six-part series focusing on increasing awareness of this disorder features Maria Cappellini, Professor of Internal Medicine at the University of Milan and Chief of the Rare Diseases Centre at the Fondazione IRCCS Policlinico Hospital, Milan, Italy.

Cappellini shares her expert insights into β-thalassaemia with our chair, internationally renowned surgeon Jonathan Sackier. With a focus on patient quality of life, topics discussed include transfusion dependency and limitations, iron chelation therapy, and target haemoglobin levels for (non-)transfusion-dependent β-thalassaemia. This on-demand webinar also features a question and answer session, which sees the experts delving further into this important topic with questions from the live audience.

This is a scientific presentation and discussion for the purpose of scientific exchange. Neither the session nor the information presented or discussed are for the promotional purpose of influencing prescribing or treatment decisions.

This session may include information about investigational products and/or uses that are not approved for use in any country or in the country of your residence.

Prescribing decisions are made by healthcare professionals. Always refer to the approved product labelling before prescribing (e.g., SmPC, US Prescribing Information).

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.